All In Biotech

Drug Trial Radar · NCT02736955

Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia

Open-Label Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia

Last checked: Nov 20, 2026Latest source record: Dec 19, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

161

Actual

Start

Jun 13, 2016

Primary completion

Jun 30, 2017

Study completion Jun 30, 2017

Sponsor

Lead sponsor
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
Sponsor type
Industry
First posted
Apr 13, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 3b, rollover study will provide participants who completed a Phase 3 valbenazine (NBI-98854) study open-label access to valbenazine (fixed doses administered once daily) for the treatment of adults with TD until valbenazine is anticipated to be available commercially or they complete 72 weeks of treatment. This study will allow enrollment of up to 150 medically stable male and female participants with TD who previously participated in and completed the NBI-98854-1304 (Kinect 3) or NBI-98854-1402 (Kinect 4) Phase 3 study.

Conditions

  • Tardive Dyskinesia

Interventions

  • ValbenazineDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Monitored for Long-term Safety of ValbenazineTime frame: 60 weeks

Locations

27 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Anaheim, California

  • Site not named

    National City, California

  • Site not named

    Norwalk, California

  • Site not named

    Oakland, California

  • Site not named

    San Bernardino, California

  • Site not named

    San Diego, California

  • Site not named

    Torrance, California

  • Site not named

    Hialeah, Florida

  • Site not named

    North Miami, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Chicago, Illinois

  • Site not named

    Shreveport, Louisiana

  • Site not named

    Worcester, Massachusetts

  • Site not named

    Cedarhurst, New York

  • Site not named

    Dayton, Ohio

  • Site not named

    Shaker Heights, Ohio

  • Site not named

    Oklahoma City, Oklahoma

  • Site not named

    Norristown, Pennsylvania

  • Site not named

    Charleston, South Carolina

  • Site not named

    Franklin, Tennessee

  • Site not named

    Memphis, Tennessee

  • Site not named

    DeSoto, Texas

  • Site not named

    Fort Worth, Texas

  • Site not named

    Irving, Texas

  • Site not named

    Salt Lake City, Utah

  • Site not named

    Petersburg, Virginia

  • Site not named

    Spokane, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.